GALT (Galectin Therapeutics) Other Current Liabilities: $0.55 Mil (As of Mar. 2026)


GALT Galectin Therapeutics Inc GALT
22 GF Score
Price $4.49
! 5 Warning Signs
View Full Analysis

What is Galectin Therapeutics Other Current Liabilities?

Galectin Therapeutics GALT -2.60% 22 Other Current Liabilities is $0.55 Mil as of Mar. 2026. GuruFocus rates GALT with a GF Score™ of 22/100. The stock has 5 warning signs investors should review.

Galectin Therapeutics's other current liabilities for the quarter that ended in Mar. 2026 was $0.55 Mil.

Galectin Therapeutics's quarterly other current liabilities declined from Sep. 2025 ($4.84 Mil) to Dec. 2025 ($1.06 Mil) and declined from Dec. 2025 ($1.06 Mil) to Mar. 2026 ($0.55 Mil).

Galectin Therapeutics's annual other current liabilities increased from Dec. 2023 ($1.13 Mil) to Dec. 2024 ($1.89 Mil) but then declined from Dec. 2024 ($1.89 Mil) to Dec. 2025 ($1.06 Mil).

Galectin Therapeutics Other Current Liabilities Related Terms

Galectin Therapeutics Other Current Liabilities Historical Data

* Premium members only.

The historical data trend for Galectin Therapeutics's Other Current Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Galectin Therapeutics Other Current Liabilities Chart

Galectin Therapeutics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Other Current Liabilities
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.73 0.97 1.13 1.89 1.06

Galectin Therapeutics Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Other Current Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.85 0.84 4.84 1.06 0.55
GALT
22GF Score
Galectin Therapeutics Inc GALT
Other Current Liabilities is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Galectin Therapeutics Other Current Liabilities Calculation

The liability a company needs to pay in the next 12 months, but not assigned to Accounts Payable or Debt. For instance, Wal-Mart (WMT) has accrued wages, salaries, valuation, bonuses, insurance liabilities, accrued tax etc. These are all included in other current liabilities.

What does a Other Current Liabilities of $0.55 Mil mean?
Galectin Therapeutics (GALT) has a Other Current Liabilities of $0.55 Mil as of Mar. 2026. Other current liabilities as record on a company's balance sheet not categorized as standard liabilities. View historical data on Galectin Therapeutics.
Is Galectin Therapeutics' Other Current Liabilities too high?
Galectin Therapeutics' current Other Current Liabilities is $0.55 Mil. Overall, Galectin Therapeutics has a GF Score™ of 22/100, reflecting its overall financial health beyond just this single metric.
How does Galectin Therapeutics' Other Current Liabilities compare to PALI and IRD?
Galectin Therapeutics' Other Current Liabilities of $0.55 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Current Liabilities for a Biotechnology company?
A good Other Current Liabilities depends on the Biotechnology industry context. However, Other Current Liabilities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Current Liabilities mean?
A high Other Current Liabilities can signal that a stock is expensive relative to its fundamentals. Other current liabilities as record on a company's balance sheet not categorized as standard liabilities. View historical data on Galectin Therapeutics. Galectin Therapeutics's current Other Current Liabilities is $0.55 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Galectin Therapeutics stock overvalued right now?
Galectin Therapeutics (GALT) has a current Other Current Liabilities of $0.55 Mil. The current Other Current Liabilities is $0.55 Mil. Galectin Therapeutics' overall GF Score™ is 22/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Current Liabilities calculated?
Other Current Liabilities is calculated from a company's financial statements. For Galectin Therapeutics (GALT), the current Other Current Liabilities is $0.55 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Galectin Therapeutics Business Description

Other Exchanges PHPN:Germany
Address 4960 Peachtree Industrial Boulevard, Suite 240, Norcross, GA, USA, 30071
Galectin Therapeutics Inc is a clinical-stage biopharmaceutical company. The company focuses on drug research and development to create new therapies for fibrotic disease, cancer, and selected other diseases. Its galectin-3 inhibitor is belapectin (GR-MD-02), which has been demonstrated in preclinical models to reverse liver fibrosis and cirrhosis.
22GF Score

Get the complete analysis for GALT

Other Current Liabilities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$4.49
Price